340B Studies and AHA Responses

A number of studies – many paid for and supported by the pharmaceutical industry – have come out in recent years examining the 340B drug savings program. The AHA has responded to a number of these studies attempting to set the record straight on the 340B program.

Study	AHA Responses
The Council of Economic Advisers - Reforming Biopharmaceutical Pricing at Home and Abroad	Drug Pricing Proposals That Focus on 340B Miss Mark (February 22, 2018)
NEJM Article - Consequences of the 340B Drug Pricing Program	What the Authors of a Recent Study Would Have Learned about the 340B Program Had They Asked (February 9, 2018)
NEJM Article - Consequences of the 340B Drug Pricing Program	Major Methodological Flaws Negate Findings from Recent 340B Study (February 5, 2018)
Moran Group Hospital Charges and Reimbursement for Drugs: Analysis of Markups Relative to Acquisition Cost	Report Misleads on Drug Prices (October 19, 2017)
AIR 340B: New Analysis Provides Evidence of Hospitals Not Using the 340B Program as Intended	Report misses mark on 340B program (October 10, 2017)
NEJM Pharmaceutical Policy Reform — Balancing Affordability with Incentives for Innovation	Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs (March 8, 2016)
GAO on MEDICARE PART B DRUGS: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals	AHA: GAO report on 340B program misses the mark (July 9, 2015)
Avalere White Paper: Hospital Acquisitions of Physician Practices and the 340B Program	AHA Responds to Latest Effort by Pharmaceutical Industry to Disparage 340B Program (June 9, 2015)
BRG Healthcare – Growth of the 340B Program: Past Trends, Future Projections	Setting the Record Straight on 340B (December 8, 2014)
Health Affairs – The 340B Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities	Health Affairs Study Gets It Wrong on 340B (October 6, 2014)

340B Drug Pricing Program

Study

AHA Responses